Press Release: European Medicines Agency recommends that Protelos/Osseor remain available but with further restrictions

The European Medicines Agency concluded its review of Protelos/Osseor and recommended further restricting the use of the medicine to patients who cannot be treated with other medicines approved for osteoporosis.

In addition these patients should continue to be evaluated regularly by their doctor and treatment should be stopped if patients develop heart or circulatory problems, such as uncontrolled high blood pressure or angina.

As recommended in a previous review, patients who have a history of certain heart or circulatory problems, such as stroke and heart attack, must not use the medicine.

• Primary Source

ESO: Background information: Press Release: PRAC recommends suspending use of Protelos/Osseor http://www.europeansources.info/record/press-release-prac-recommends-suspending-use-of-protelos-osseor/

ESO: Background information: Press Release: Recommendation to restrict the use of Protelos/Osseor (strontium ranelate) http://www.europeansources.info/record/press-release-recommendation-to-restrict-the-use-of-protelos-osseor-strontium-ranelate/

---